m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05877
 [1]
m6A modification RPPH1 RPPH1 hnRNPA1 : m6A sites Indirect Enhancement Non-coding RNA RPPH1 IGF2BP2  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) READER
 Regulator Info 
m6A Target ribonuclease P RNA component H1 (RPPH1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Ribonuclease P RNA component H1 (RPPH1) LncRNA View Details
Regulated Target Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators indirectly modulate the functionality of ncRNAs through downstream signaling pathways
Crosstalk Summary Hypoxia-induced transcription factor HIF1A facilitates the expression and functions of ribonuclease P RNA component H1 (RPPH1) in breast cancer cells and its packaging into exosomes via hnRNPA1. Exosomal RPPH1 promotes breast cancer angiogenesis and metastasis through stabilizing the Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2)/FGFR2 axis
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Pathway Response PI3K-Akt signaling pathway hsa04151
Cell Process Proteon degradation
Cell metastasis
RNA stability
In-vitro Model
 MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
HEK293T Normal Homo sapiens CVCL_0063
HUVECs (Human Umbilical Vein Endothelial Cells)
bEnd.3 Cerebrovascular endothelioma cells from mice Mus musculus CVCL_0170
In-vivo Model For the Matrigel plug assay, HUVECs (1\(\times\)107 cells) incubated with MDA-MB-231-derived exosomes or transfected with the corresponding plasmids were suspended in 100 μl PBS and were mixed with 100 μl the Matrigel basement membrane matrix (Corning), then injected subcutaneously into the nude mice (female, 6-week-old, BALB/c) (n = 6) in the dorsal region.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) 15 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name ISIS 112000 Investigative [2]
External Link
TTD: D00LSM
 Compound Name ISIS 112022 Investigative [2]
External Link
TTD: D00SQD
 Compound Name ISIS 112019 Investigative [2]
External Link
TTD: D04XOE
 Compound Name ISIS 112005 Investigative [2]
External Link
TTD: D06QZK
 Compound Name ISIS 112002 Investigative [2]
External Link
TTD: D07FSX
 Compound Name ISIS 112023 Investigative [2]
External Link
TTD: D07RUF
 Compound Name ISIS 111992 Investigative [2]
External Link
TTD: D0D9OL
 Compound Name ISIS 112003 Investigative [2]
External Link
TTD: D0GD1R
 Compound Name ISIS 111997 Investigative [2]
External Link
TTD: D0H0YU
 Compound Name ISIS 112004 Investigative [2]
External Link
TTD: D0H6OL
 Compound Name ISIS 112001 Investigative [2]
External Link
TTD: D0N7OK
 Compound Name ISIS 112024 Investigative [2]
External Link
TTD: D0QU6S
 Compound Name ISIS 112020 Investigative [2]
External Link
TTD: D0T0XZ
 Compound Name ISIS 111993 Investigative [2]
External Link
TTD: D0Y4TS
 Compound Name ISIS 112021 Investigative [2]
External Link
TTD: D0Z4RI
2C60: Breast cancer 2 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Entrectinib Approved [3]
Synonyms
1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
    Click to Show/Hide
External Link
CID: 25141092
TTD: D0O0LS
DrugBank: DB11986
 Compound Name Everolimus Approved [4]
External Link
CID: 6442177
TTD: D09ZSC
DrugBank: DB01590
References
Ref 1 Hypoxia induced cellular and exosomal RPPH1 promotes breast cancer angiogenesis and metastasis through stabilizing the IGF2BP2/FGFR2 axis. Oncogene. 2025 May;44(18):1316-1318. doi: 10.1038/s41388-025-03422-z.
Ref 2 US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
Ref 3 Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.
Ref 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015